Royalty Pharma plc Class A Ordinary Shares
RPRX
$59.02
+0.51%
Royalty Pharma is the largest buyer of biopharmaceutical royalties, entitling it to payments based on sales of drugs like Imbruvica, Tysabri, and Vertex's cystic fibrosis franchise. As a dominant player in the royalty market, it offers a unique, asset-light model with high margins and diversified revenue streams. The current investor narrative centers on its accelerating revenue growth, expanding pipeline of development-stage royalties, and strong cash flow generation, which have driven significant share price appreciation and attracted bullish analyst attention.…
RPRX
Royalty Pharma plc Class A Ordinary Shares
$59.02
RPRX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Royalty Pharma plc Class A Ordinary Shares's 12-month outlook, with a consensus price target around $59.89 and implied upside of +1.5% versus the current price.
Average Target
$59.89
0 analysts
Implied Upside
+1.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$46 - $66
Analyst target range
Royalty Pharma is covered by 9 analysts, with a consensus recommendation of 'Buy' (mean score 1.6 on a 1-5 scale, where 1 is Strong Buy). The average target price is $59.89, implying a modest 2.9% upside from the current price of $58.18. The distribution shows 0 holds and 0 sells, indicating unanimous bullish sentiment. The target range spans from $46.00 (low) to $66.00 (high). The high target of $66.00 assumes continued growth acceleration and multiple expansion, while the low target of $46.00 prices in potential headwinds like slower royalty income or competitive pressures. Recent ratings from TD Cowen, Citigroup, JP Morgan, UBS, and Morgan Stanley are all bullish, with UBS upgrading from Neutral to Buy in January 2026. The relatively narrow spread between low and high targets (20% range) suggests moderate conviction among analysts.
Bulls vs Bears: RPRX Investment Factors
Royalty Pharma presents a compelling bull case driven by accelerating revenue growth, exceptional margins, and strong free cash flow generation. The stock's PEG ratio of 0.78 and forward PE of 10.4x suggest it is undervalued relative to its growth prospects, while unanimous analyst buy ratings and a low beta provide additional comfort. However, the stock has already rallied 64% over the past year, leaving limited upside to the average analyst target of $59.89. The high EV/Sales multiple and concentration risk in key royalties are notable concerns. The single most important tension is whether the company can sustain its revenue growth acceleration and margin expansion to justify its current valuation. If growth continues to accelerate, the stock could re-rate higher; if it decelerates, the premium multiple could compress. Currently, the bull case has stronger evidence given the strong fundamentals and attractive PEG ratio.
Bullish
- Strong Revenue Growth Acceleration: Revenue grew 10.97% YoY in Q1 2026 to $630.6M, with sequential acceleration from $568.2M in Q1 2025 to $622.0M in Q4 2025. This consistent upward trajectory supports the investment case for a unique, high-margin business model.
- Exceptional Profitability and Margins: Net margin expanded to 46.8% in Q1 2026 from 41.9% a year ago, while gross margin is near 100% (99.8%). Operating margin reached 100.3%, reflecting the asset-light royalty model with minimal cost of revenue.
- Attractive Valuation with PEG Ratio Below 1: The trailing PE of 16.6x and forward PE of 10.4x are reasonable for a high-margin, cash-generative business. The PEG ratio of 0.78 suggests the stock is undervalued relative to its growth rate.
- Massive Free Cash Flow Generation: TTM free cash flow is $2.65 billion, yielding approximately 15.9% based on market cap. This provides ample coverage for dividends and investments, with a payout ratio of 49.1% and dividend yield of 2.27%.
Bearish
- Limited Upside to Average Analyst Target: The current price of $58.18 is already near the average analyst target of $59.89, implying only 2.9% upside. The stock has rallied 64% over the past year, potentially pricing in much of the good news.
- High Valuation on EV/Sales Basis: EV/Sales of 15.3x is elevated, reflecting a premium for the royalty model. While PE is reasonable, the high EV/Sales multiple could compress if growth decelerates or if interest rates remain high.
- Concentration Risk in Key Royalties: The portfolio relies heavily on a few key drugs like Imbruvica, Tysabri, and Vertex's CF franchise. Any negative clinical or regulatory news for these products could materially impact revenue.
- Low Beta May Limit Participation in Market Rally: With a beta of 0.42, the stock offers downside protection but may underperform in a strong bull market. Investors seeking aggressive growth may find better opportunities elsewhere.
RPRX Technical Analysis
Royalty Pharma is in a sustained uptrend, with the stock up 64.0% over the past year, significantly outperforming the S&P 500's 18.4% gain. The current price of $58.18 sits at 97.9% of its 52-week range ($34.08–$59.44), indicating strong momentum and positioning near the highs, which suggests bullish sentiment but also potential overextension. The stock has rallied from its 52-week low of $34.08 to current levels, reflecting a powerful recovery and sustained buying pressure. Short-term momentum is accelerating, with a 1-month gain of 8.3% and a 3-month gain of 16.4%, both outpacing the S&P 500's respective returns of 0.3% and 4.7%. The 1-month relative strength of 8.0% confirms near-term outperformance, and the 6-month gain of 47.1% aligns with the longer-term uptrend, showing no divergence. The stock's beta of 0.42 indicates it is significantly less volatile than the market, making it a lower-risk holding. Key support lies near the 52-week low of $34.08, while resistance is at the 52-week high of $59.44. A breakout above $59.44 would signal further upside, while a breakdown below $34.08 would be a bearish reversal. The low beta suggests the stock may lag in a market rally but offers downside protection.
Beta
0.42
0.42x market volatility
Max Drawdown
-7.9%
Largest decline past year
52-Week Range
$34-$59
Price range past year
Annual Return
+63.9%
Cumulative gain past year
| Period | RPRX Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +0.6% |
| 3m | +19.5% | +3.4% |
| 6m | +46.1% | +7.1% |
| 1y | +63.9% | +16.4% |
| ytd | +51.9% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RPRX Fundamental Analysis
Revenue is growing steadily, with Q1 2026 revenue of $630.6 million, up 10.97% year-over-year from $568.2 million in Q1 2025. The multi-quarter trend shows acceleration: Q1 2025 revenue was $568.2 million, Q2 2025 was $578.7 million, Q3 2025 was $609.3 million, and Q4 2025 was $622.0 million, indicating consistent sequential growth. The primary driver is the Financial Royalty Assets segment, which contributed $595.0 million in the latest quarter, while Royalty Income, Other added $35.6 million. This growth trajectory supports the investment case for a company with a unique, high-margin business model. Profitability is robust, with net income of $295.0 million in Q1 2026 and a net margin of 46.8%, up from 41.9% in Q1 2025. Gross margin is near 100% (99.8% in Q1 2026), reflecting the royalty-based model with minimal cost of revenue. Operating margin expanded to 100.3% in Q1 2026 from 94.0% in Q1 2025, driven by operating leverage. The company is highly profitable and generating strong returns, with ROE of 11.9% and ROA of 5.5%. The balance sheet is healthy, with a debt-to-equity ratio of 1.38 and a current ratio of 0.97, indicating adequate liquidity. Free cash flow (TTM) is $2.65 billion, providing ample coverage for dividends and investments. The FCF yield is approximately 15.9% based on market cap, signaling strong cash generation relative to valuation.
Quarterly Revenue
$630576000.0B
2026-03
Revenue YoY Growth
+11.0%
YoY Comparison
Gross Margin
99.8%
Latest Quarter
Free Cash Flow
$2.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RPRX Overvalued?
Since net income is positive, the trailing PE ratio of 16.6x is the primary valuation metric, with a forward PE of 10.4x. The gap between trailing and forward PE implies the market expects significant earnings growth, consistent with the company's growth trajectory. The PEG ratio of 0.78 suggests the stock is undervalued relative to its growth rate. Compared to the industry, Royalty Pharma trades at a premium on a PS basis (7.0x vs. industry average not provided, but the EV/Sales of 15.3x is high). However, its PE of 16.6x is reasonable for a high-margin, cash-generative business. The premium is justified by its dominant market position, near-100% gross margins, and strong free cash flow. Historically, the trailing PE has ranged from 4.7x (Q4 2023) to 747.5x (Q1 2024), with the current 16.6x near the lower end of the range, suggesting the stock is not overvalued relative to its own history. The PB ratio of 2.58x is also below its historical highs of over 3.0x, indicating potential value.
PE
16.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Royalty Pharma's debt-to-equity ratio of 1.38 indicates moderate leverage, with interest expense of $93.7 million in Q1 2026. While the company generates ample free cash flow ($2.65 billion TTM) to service debt, a sustained rise in interest rates could increase refinancing costs. Revenue concentration is a risk, as the top royalties (Imbruvica, Tysabri, Vertex CF) account for a significant portion of income. Any loss of exclusivity or negative clinical data for these drugs could materially reduce royalty income. The company's net margin of 46.8% is high but could be pressured if it needs to increase spending on pipeline acquisitions.
Market & Competitive Risks: The stock's beta of 0.42 suggests low correlation with the broader market, which is a double-edged sword: it provides downside protection but may lag in a strong bull market. The EV/Sales multiple of 15.3x is elevated relative to the broader market, making the stock vulnerable to multiple compression if growth decelerates or if interest rates remain high. Competition from other royalty buyers could increase, potentially driving up acquisition prices and reducing future returns. Regulatory changes affecting drug pricing or patent law could also impact the value of the royalty portfolio.
Worst-Case Scenario: In a severe downturn, a combination of slower revenue growth, rising interest rates, and negative news from key drugs could drive the stock to its 52-week low of $34.08, representing a 41.4% decline from the current price of $58.18. This scenario would likely require multiple compression (PE falling to ~10x) and a significant reduction in forward earnings estimates. While the company's asset-light model provides some downside protection, the high starting valuation amplifies the risk of a sharp correction.